Inhibitors of angiogenesis in a clinical perspective

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 723-727

  Voest, Emile E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiogenesis; Applications; Cancer; Clinical testing

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BATIMASTAT; FUMAGILLOL CHLOROACETYLCARBAMATE; MARIMASTAT; METALLOPROTEINASE INHIBITOR; THROMBOCYTE FACTOR 4; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; HUMAN; METHODOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW;

EID: 0029912061     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00001     Document Type: Review

References (36)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis, Cell 1994; 79: 185-8.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
4. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971; 285: 1182-6.
5. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-7.
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
7. Auerbach W, Auerbach R. Angiogenesis inhibition; a review. Pharmacol Ther 1994; 63: 265-311.
8. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastasts: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-53.
9. Weinstat Saslow D, Steeg PS. Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 1994; 8: 401-7.
10. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-82.
11. Senger DR, van de Water I., Brown LF et al Vascular permeability factor (VPE VHGF) in tumor biology Cancer Metastasis Rev 1993; 12: 303-24.
12. Nomura M, Yamagishi S, Harada S, et al. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes J Biol Cbem 1995; 270: 28316-24.
13. Villaschi S, Nicosia RE Paracrine interactions between fibroblasts and endothelial cells in a serum-free coculture model. Modulation of angiogenesis and collagen gel contraction. Lab Invest 1994; 71: 291-9.
14. Belotti D, Nicoletti I, Vergani V. et al. Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor induced angiogenesis. Proc Am Ass Cancer Res 1996; 37: 57 (abstr 397).
15. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-6.
16. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52: 6702-4.
17. Griffioen AW, Damen CA, Martinotti S, Blijham GH, Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 1996; 56: 1111-7.
18. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative FIk-1 mutant. Nature 1994; 367: 576-9.
19. Harris AL, Zhang H, Moghaddam A, et al. Breast cancer angiogenesis-new approaches to therapy via antiangiogenesis. hypoxic activated drugs, and vascular targeting. Breast Cancer Res Treat 1996; 38: 97-108.
20. Millauer B, Longhi MP, Plate KH, et al. Dominantnegative inhibition of FIk-1 suppresses the growth of many tumor typs in vivo. Cancer Res 1996; 56: 1615-21.
21. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
22. Warren RS, Yuan H, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
23. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-28.
24. Zucker MB, Katz IR. Platelet factor 4. production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991; 198: 693-702.
25. Kolber DL, Knisely TL, Maione TE. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4. J Natl Cancer Inst 1995; 87: 304-9.
26. Cheresh DA. Structural and biologic properties of integrin-mediated cell adhesion. Clin Lab Med 1992; 12: 217-36.
27. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995; 270: 1500-2.
28. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-64.
29. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994; 264: 569-71.
30. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990; 348: 555-7.
31. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993; 53: 5233-6.
32. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470). Cancer Res 1993; 53: 4262-7.
33. Antoine NA, Daukandt M, Heinen E, Simar LJ, Castronovo V. In vitro and in vivo stimulation of the murine immune system by AGM-1470, a potent angiogenesis inhibitor. Am J Pathol 1996; 148: 393-8.
34. Ingber DE. Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. Semin Cancer Biol 1990; 3: 57-63.
35. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8.
36. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33.